Svetlana G Palshina

Svetlana G Palshina

Auto-generated profile, based on publicly available information

Svetlana G Palshina

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VVV. I. Vasilyev
V. I. Vasilyev
SPS. G. Palshina
S. G. Palshina
APA. I. Pavlovskaya
A. I. Pavlovskaya
NKN. V. Kokosadze
N. V. Kokosadze
BCB. D. Chaltsev
B. D. Chaltsev
ЧДЧальцев Богдан Дмитриевич
Чальцев Богдан Дмитриевич
Idiopathic multicentric Castlemans disease is a rare lymphoproliferative disorder that has many similar laboratory, radiological, clinical and pathological manifestations with various conditions, including IgG4-related disease. Increased activity of cytokines, especially interleukin-6, leads to systemic inflammatory symptoms with the development of lymphadenopathy and rarely extranodal lesions. Histological changes in the lymph nodesin hyaline vascular and plasma cell variants of Castlemans disease are hardly distinguishable from the pattern of reactive, tumor and IgG4-related lymphadenopathy. Idiopathic multicentric Castlemans disease can be diagnosed only when infection with human herpesvirus-8 type and human immunodeficiency virus is excluded. In the article, the authors describe two cases of idiopathic multicentric Castlemans disease, including the first world literature description of extranodal damage of the hip muscle in this disorder. In addition, the authors gave a review of the literature on the main clinical, laboratory and morphological manifestations, which allow confirming the diagnosis of Castlemans disease.

1 September 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
VGVadim Gorodetskiy
Vadim Gorodetskiy
NPNatalya Probatova
Natalya Probatova
NKNatalia A Kupryshina
Natalia A Kupryshina
SPSvetlana G Palshina
Svetlana G Palshina
TOTatiana Obukhova
Tatiana Obukhova
ASAndrey Sudarikov
Andrey Sudarikov
The peculiar features of T-cell large granular lymphocytic leukemia (T-LGLL) are its association with autoimmune disorders (particularly with rheumatoid arthritis (RA)) and a broad spectrum of B-cell lymphoproliferative disorders. However, association of T-LGLL with mantle cell lymphoma (MCL) is extremely rare. Here, we describe a case of an 80-year-old man admitted with suspected Felty’s syndrome. The blood count showed white blood cells at 2.2× 109/L, with 3% neutrophils, 88% lymphocytes, and at 0.66× 109/L LGLs. The spleen had been removed 43 months prior to the admission due to suspected B-cell splenic lymphoma. Re-examination of the spleen revealed cyclin D1+ and SOX11− lymphocytes in the inner part of the unexpanded mantle zones of the white pulp follicles, thus displaying a so-called in situ histologic pattern of MCL, and in small clusters in the red pulp. The splenic cords were moderately expanded by lymphocytes expressing CD3, TIA1, and granzyme B but not CD4 and CD8. Monoclonal rearrangements of the immunoglobulin heavy chain gene and the T-cell receptor (TCR) gamma and delta chain genes, polyclonal rearrangements of the TCR beta chain gene, mutation of the signal transducer and activator of transctiption 3 gene (c.1940A>T; p.N647I), and t(11;14)(q13;q32) translocation were identified in the spleen sample. Flow cytometry of bone marrow revealed a population of TCR γδ+, CD3+, CD4−, CD5−, CD7+, CD8−, CD16−, CD56−, and CD57− lymphocytes. Fragment analysis demonstrated identical TCR gene clonal rearrangement patterns in the spleen and bone marrow samples. In this study, we describe the first case of simultaneous presentation of γδ T-LGLL and leukemic non-nodal MCL (L-NN-MCL) in a patient with RA and present morphological findings of L-NN-MCL in the spleen.

15 December 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
VVV. I. Vasil'EV
V. I. Vasil'EV
BCB. D. Chal'TSev
B. D. Chal'TSev
VGVadim Gorodetskiy
Vadim Gorodetskiy
SPS. G. Pal'SHina
S. G. Pal'SHina
NSN. S. Shornikova
N. S. Shornikova
ГВГайдук Игорь Викторович
Гайдук Игорь Викторович
Despite the large number of studies devoted to the study of systemic sclerosis (SSc), the high risk of developing lymphomas in this disease, the relationship of their development with certain subtypes of SSc and specific SSc-associated autoantibodies is still debated in the literature. Aim.To study demographic, clinical, laboratory and immunological characteristics of patients with a combination of primary Sjogrens syndrome (pSS) and SSc and diagnosed lymphoproliferative diseases (LPDs); to characterize morphological/immunomorphological variants and course of non-Hodgkins lymphomas (NHL), developing in patients with these rheumatic diseases (RDs). Materials and methods.In 19982018 at the Nasonova Research Institute of Rheumatology, 13 patients with clinical and laboratory manifestations of pSS (12) and SSc (13) were diagnosed with various lymphoproliferative diseases (LPDs). In 3 cases, an induced RD was observed: 1 case of a diffuse, rapidly progressive form of SSc, 2 cases of pSS in combination with a limited form of SSc after chemotherapy and radiation therapy of Hodgkins lymphoma (1), B-cell NHL (1) and CR of the breast (1) respectively. The first 2 cases were excluded from the analysis, since the development of lymphomas is not pathogenetically associated with RD. Results.Of 11 patients with LPDs, 10 after a long course of RDs were diagnosed with NHL [MALT lymphoma of the parotid salivary glands 7, disseminated MALT lymphoma 2, disseminated MALT lymphoma with transformation into diffuse large B-cell lymphoma (DLBCL) 1]. RDs debuted with Raynauds phenomenon (RP) in 64.5% and pSS manifestations in 45.5% of patients. Stomatological manifestations of pSS were characterized by recurrent parotitis in 36%, significant parotid gland enlargement with massive infiltration of labial salivary glands (focus score 4) in 100%, severe xerostomia in 70%, extraglandular manifestations and lymphadenopathy in 50% of patients. The course of the SSc was characterized by mild RP with various types of capillaroscopic changes and mild lung changes and non-significant progression during long-term follow-up (median 22 years). The entire spectrum of SSс specific antibodies (anticentromere antibodies 60%, antibodies to ribonucleoprotease III 30%, Pm/Scl 10%), excepting antibodies to topoisomerase I, as well as pSS specific autoantibodies (antiRo/La 70%, RF (rheumatoid factor) 90%), were detected in patients with a combination of these RDs. Conclusion.pSS is often combined with a limited form of SSc regardless of the type of autoantibodies detected. The presence of pSS, rather than SSc, is a high-risk factor for the development of NHL in this group of patients. The patients with pSS and SSc are characterized by a steady progression of pSS with a slow and mild course of SSc throughout the observation period. The development of severe stomatological manifestations and high immunological activity of pSS contribute to the development of localized MALT lymphomas (70%) and disseminated MALT lymphomas (30%) with primary lesions of the salivary glands and transformation into DLBCL in case of their late diagnosis. The optimal method for preventing the development of NHL in this group of patients is the early diagnosis of pSS, the appointment of alkylating cytotoxic agents and/or anti-B-cell therapy in the early stages of pSS. Given the possibility of transformation of localized NHL into DLBCL, for early diagnosis, minimally invasive surgical biopsies of significantly enlarged parotid salivary glands should be performed before glucocorticoids are prescribed. Detection of positive B-cell clonality and lymphoepithelial lesions in the parotid salivary gland is considered a predictor of MALT lymphoma development during follow-up. Localized and disseminated MALT lymphomas in patients with pSS and SSc respond well to therapy, in contrast to MALT lymphomas transformed into DLBCL.

14 February 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
SRS.G. Radenska-Lopovok
S.G. Radenska-Lopovok
MKM.S. Karanova
M.S. Karanova
AZA.S. Zanozin
A.S. Zanozin
ERE.B. Rodionova
E.B. Rodionova
SPS.G. Palshina
S.G. Palshina
VVV.I. Vasilev
V.I. Vasilev
Результаты морфологического исследования малых слюнных желез могут быть использованы для оценки активности болезни Шегрена и при решении вопроса об адекватной терапии. Существующий протокол The Sjögren’s International Clinical Collaborative Alliance (SICCA) предписывает методологию исследования биоптатов при подозрении на болезнь Шегрена, однако специалисты по-разному трактуют данные анализа гистологических препаратов. ЦЕЛЬ ИССЛЕДОВАНИЯ Ретроспективный анализ биоптатов малых слюнных желез у больных с достоверным диагнозом болезни Шегрена для выявления морфологических форм сиаладенита, а также определения индекса морфологической активности у российских пациентов. МАТЕРИАЛ И МЕТОДЫ Изучены биоптаты малых слюнных желез 92 больных болезнью Шегрена и 42 пациентов без ревматического заболевания. РЕЗУЛЬТАТЫ У 69 больных болезнью Шегрена был выявлен очаговый лимфоцитарный сиаладенит. Индекс морфологической активности у больных болезнью Шегрена составил 7,32 (от 2,8 до 14,17). У больных без ревматических заболеваний этот индекс был 0,48 (p≤0,05). Больные со сливными лимфоцитарными инфильтратами нуждаются в иммуногистохимическом исследовании и динамическом наблюдении для исключения лимфопролиферативных заболеваний. ЗАКЛЮЧЕНИЕ Индекс морфологической активности сиаладенита при болезни Шегрена составляет от 2,8 до 14,17 и отражает активность основного заболевания. Он должен учитываться в диагностике и назначении адекватной терапии. Дальнейшее изучение корреляций морфологических и клинико-лабораторных показателей приведет к уточнению критериальных признаков заболевания.

13 May 2021 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
BCB. D. Chaltsev
B. D. Chaltsev
VVV. I. Vasiliev
V. I. Vasiliev
SPS. G. Palshina
S. G. Palshina
ATA. V. Torgashina
A. V. Torgashina
ESE. V. Sokol
E. V. Sokol
ЮХЮ. И. Хван
Ю. И. Хван
Objective: to compare clinical and laboratory manifestations in 2 groups of patients with primary Sjogren’s syndrome (pSS): with and without anticentromere antibodies (ACA); compare the incidence, clinical and laboratory characteristics of lymphomas in these two groups.Materials and methods. We examined 119 patients with ACA-positive pSS (pSS-ACA+). pSS was diagnosed based on Russian 2001 criteria, systemic sclerosis (SSc) – criteria ACR/EULAR 2013. To diagnose liver diseases, the level of transaminases, alkaline phosphatase and antimitochondrial antibodies (AMA) was determined, as well as liver biopsy. The diagnosis of primary biliary cholangitis (PBC) was established according to the recommendations of the American Association for the Study of Liver Diseases, the Russian Gastroenterological Association and the Russian Society for the Study of the Liver. Lymphomas were diagnosed according to histological, immunohistochemical and molecular studies of affected organs biopsies, according to the classification of the World Health Organization. A combination of pSS and SSc was diagnosed in 37 patients, and they were excluded from further analysis. We compared clinical and laboratory features in patients with pSS-ACA+ (n=82) and ACA-negative pSS (pSS-ACA–, n=64) and characterized lymphomas in the pSS-ACA+ (n = 14) and pSS-ACA– (n=10) groups.Results and discussion. In patients with pSS-ACA+, a later age of disease onset was revealed, the duration of the disease before lymphoma development did not differ. In patients with pSS-ACA+, we found a lower frequency of rheumatoid factor (RF), antibodies to Ro (anti-Ro) and La (anti-La), decreased C3-complement, hypergammaglobulinemia, increased IgG concentration, CRP, increased ESR, leukopenia and anemia. 51.2% of patients with pSS-ACA+ were seronegative for anti-Ro, anti-La and RF. Patients with pSS-ACA+ had a higher frequency of AMA and elevated IgM. The incidence of cryoglobulinemia and paraproteinemia did not differ. The frequency of recurrent parotitis in pSS-ACA+ was significantly lower, there were no differences in the frequency and severity of other signs of salivary and lacrimal gland damage. PBC and epitheliitis of the biliary ducts in patients with pSS-ACA+ were detected significantly more often. Damage to the peripheral nervous system, lungs, hypergammaglobulinemic purpura, arthralgia and autoimmune thyroiditis were significantly more often detected in the group of patients with pSS-ACA–. In the pSS-ACA+ group, Raynaud’s phenomenon was significantly more frequent, mainly with scleroderma-type capillaroscopic abnormalities. There was no difference in the frequency of other signs characteristic of SSc. MALT lymphomas were diagnosed in the study groups with the same frequency. Patients with lymphomas in the pSS-ACA+ group were characterized by significantly higher laboratory activity. All patients with lymphomas in both groups showed persistent parotid salivary gland enlargement. Lymphomas in both groups developed in patients with late stage salivary and lacrimal gland damage, systemic manifestations of pSS in both groups were rare.Conclusion. pSS-ACA+ is an independent subtype of pSS, which has a number of significant clinical and laboratory differences from the “classic” variant of the disease. ACA in pSS are associated with a low frequency of anti-Ro, anti-La, and RF, as well as an increased risk of PBC and limited SSc. MALT lymphomas in the pSS-ACA+ and pSS-ACA– groups developed with the same frequency and were associated with the progression of glandular damage, regardless of the presence of systemic manifestations.